Eyepoint Pharmaceuticals' (EYPT) "Neutral" Rating Reaffirmed at Mizuho

Key Points

• Mizuho reaffirmed a “neutral” rating on EyePoint Pharmaceuticals and set a $0.50 price target, implying 13.64% upside from the prior close.
• Analyst sentiment remains mixed but broadly cautious: two analysts rate the stock a Buy, eight Hold, and two Sell, resulting in a consensus “Hold” rating and a $22.25 average target price.
• EyePoint’s shares opened at $0.44, near their 52-week low, while the company reported a quarterly EPS loss of $1.09 and continues to face sharply negative margins and expectations for a full-year loss.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report)'s stock had its "neutral" rating reissued by research analysts at Mizuho in a research note issued to investors on Tuesday, Marketbeat.com reports. They currently have a $0.50 price objective on the stock. Mizuho's target price would suggest a potential upside of 13.64% from the stock's previous close.

Several other research firms also recently weighed in on EYPT. Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals from an "overweight" rating to a "neutral" rating in a research note on Monday, August 17th. Citigroup reduced their price objective on Eyepoint Pharmaceuticals to $17.00 and set a "buy" rating for the company in a research note on Tuesday, August 18th. Wall Street Zen upgraded Eyepoint Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Sunday, September 27th. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $5.00 target price on shares of Eyepoint Pharmaceuticals in a report on Tuesday, August 18th. Finally, Guggenheim lowered Eyepoint Pharmaceuticals from a "buy" rating to a "neutral" rating in a research report on Monday. Two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $22.25.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT opened at $0.44 on Tuesday. The firm has a market capitalization of $37.93 million, a PE ratio of -0.12 and a beta of 1.67. Eyepoint Pharmaceuticals has a 1-year low of $0.40 and a 1-year high of $19.11. The company's fifty day moving average price is $4.77 and its 200-day moving average price is $10.30.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.08). The firm had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. As a group, research analysts anticipate that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. KBC Group NV acquired a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth approximately $29,000. Janney Montgomery Scott LLC grew its stake in Eyepoint Pharmaceuticals by 14.8% in the 1st quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company's stock valued at $391,000 after acquiring an additional 3,900 shares during the period. Baird Financial Group Inc. grew its stake in Eyepoint Pharmaceuticals by 16.4% in the 2nd quarter. Baird Financial Group Inc. now owns 32,732 shares of the company's stock valued at $468,000 after acquiring an additional 4,613 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in Eyepoint Pharmaceuticals in the 2nd quarter valued at $72,000. Finally, Pictet Asset Management Holding SA purchased a new stake in Eyepoint Pharmaceuticals in the 1st quarter worth $141,000. 99.41% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint plans to reduce operating expenses and concentrate resources on its late-stage DURAVYU program for DME. The narrower focus could extend the company’s cash runway and preserve value in its remaining lead program. EyePoint Announces Strategic Prioritization
• Neutral Sentiment: Unusual options activity included purchases of 7,885 call contracts, approximately 69% above typical daily call volume. This may indicate speculative interest or expectations of a rebound, but it does not change the company’s fundamental outlook.
• Negative Sentiment: EyePoint reported disappointing topline results from the LUCIA Phase 3 trial of DURAVYU in wet AMD. The setback led the company to halt related clinical trials early, removing a major potential catalyst and raising doubts about the drug’s commercial prospects in the market. EyePoint Announces Topline Results from LUCIA
• Negative Sentiment: The company announced a 53% workforce reduction as part of its restructuring after the clinical-trial setback. Although the cuts should lower expenses, they also signal a substantially reduced operating plan and weaker near-term growth prospects. EyePoint Pharmaceuticals to Cut 53% of Workforce
• Negative Sentiment: Guggenheim downgraded EYPT from “buy” to “neutral,” while Jefferies moved from “buy” to “hold.” Jefferies assigned a $1.00 price target, implying substantial upside from the current level, but the downgrade reflects sharply reduced confidence following the LUCIA results.
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations on behalf of shareholders who suffered losses. The inquiry adds legal and reputational risk, although it does not establish wrongdoing. EyePoint Pharmaceuticals Investigation Notice

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint's commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.